Quarterly ResultMay 12, 2026, 04:08 PM
Nkarta Q1 Results; Outpatient Dosing, Ntrust-2 Expansion; Cash into 2029
AI Summary
Nkarta, Inc. reported its first quarter 2026 financial results and significant corporate highlights. The company reached a regulatory agreement with the FDA to amend its protocol, allowing outpatient dosing in community settings, re-dosing, removal of overnight monitoring, and expansion of the Ntrust-2 study to include rheumatoid arthritis patients. Enrollment continues in Ntrust-1 and Ntrust-2, with initial clinical data expected in 2026. Nkarta ended the quarter with $266.7 million in cash, cash equivalents, and investments, which is projected to fund operations into 2029, while reporting a net loss of $27.8 million for the quarter.
Key Highlights
- Regulatory agreement with FDA allows outpatient dosing and Ntrust-2 expansion to include rheumatoid arthritis.
- Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2.
- Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical meeting in 2026.
- Cash, cash equivalents, and investments totaled $266.7 million as of March 31, 2026.
- Cash balance expected to fund operations into 2029.
- Net loss was $27.8 million, or $0.37 per basic and diluted share, for Q1 2026.
- Research and development (R&D) expenses were $25.0 million for Q1 2026.
- General and administrative (G&A) expenses were $5.9 million for Q1 2026.
Price Impact
More from NKTX